<DOC>
	<DOC>NCT00641472</DOC>
	<brief_summary>A one year study comparing the safety and effectiveness of Pulmicort (0.5mg strength given once a day in the evening) with either 4 or 5mg strength SINGULAR (given once a day in the evening) in children with asthma aged 2 to 8. If allocated to SINGULAR treatment, children aged between 2 and 5 will receive 4mg strength SINGULAR and those aged between 6 and 8 will receive 5mg strength SINGULAR.</brief_summary>
	<brief_title>Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Aged 2 to 8 at study entry At least 3 episodes of wheezing in the previous year that lasted more than 24 hours and affected sleep or symptoms of mild persistent asthma use of b2 agonist treatment on at least 3 of 7 consecutive days or run in Severe or unstable asthma any significant finding at a physical exam an exacerbation of asthma in the 30 days before entering the study that might affect study results in judgement of the study doctor</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Pulmicort</keyword>
	<keyword>Children</keyword>
	<keyword>paediatrics</keyword>
	<keyword>budesonide</keyword>
</DOC>